|
|
Make sure your computer is equipped with a sound
card, which enables you to hear audio recordings.
Then you will need to download a copy of RealPlayer™
Plus 8.0 or RealPlayer™ 8 Basic (free version)
from the RealAudio Web site at http://www.real.com/products/player/index.html
|
Highlights
from:
SUNDAY | MONDAY | TUESDAY | WEDNESDAY
SUNDAY,
MARCH 18
Results from Sunday
8:15–9:00
a.m.
ACC Opening Media Briefing
Presenters: ACC President George Beller, MD, ACC 2001
Program Committee Chair John DiMarco, MD, PhD, ACC 2001
Program Committee Co-chair Sanjiv Kaul, MD, all of the
Univ. of Va., Charlottesville; Sharon Hunt, MD, Stanford
Univ.; Eric Williams, MD, Ind. Univ. Sch. of Med., Indianapolis;
and Jeffrey Popma, MD, Brigham and Women's Hosp., Boston
 Listen
to the news conference.
9:00–10:00
a.m.
Open to attend late-breaking clinical trials sessions:
- Arrhythmia/Device
Trial Update, 8-10 a.m., #61
- Late-Breaking
Trials in Interventional Cardiology, 8:45-10 a.m.,
#22
10:30–11:15
a.m.
Which is the
best option—medical therapy, angioplasty, stents,
or surgery?
- Restenosis
Intra-Stent: Balloon Angioplasty vs. Elective Stenting.
Results of a Randomized Trial—Fernando Alfonso,
MD, Univ. San Carlos, Madrid, Spain, 3/18, 8:45 a.m.,
#22-1
- The
Stent or Surgery Trial (SoS)—Rodney Stables,
MD, Royal Liverpool Univ. Hosp. and Cardiothoracic
Ctr., Liverpool, United Kingdom, 3/18, 9:20 a.m.,
#22-7
-
The Medicine, Angioplasty, or Surgery Study (MASS
II): A Randomized, Controlled Clinical Trial of Medical
Therapy, Coronary Angioplasty, or Bypass Surgery for
Multivessel Coronary Artery Disease—Whady Hueb,
MD, Heart Inst. at Univ. of Sao Paulo, Brazil, 3/18,
9:45 a.m., #22-9
Moderator:
David Faxon, MD, Univ. of Chicago
Listen
to the news conference.
11:30
a.m.–12:15 p.m.
Clinical trials examine
a novel pacing technique to prevent atrial fibrillation
and radiation for in-stent restenosis
- Dual-Site
Atrial Pacing for Prevention of Atrial Fibrillation
Trial (DAPPAF)—Sanjeev Saksena, MD, Atlantic
Health Sys., Millburn, N.J., 3/18, 9:15 a.m., #61-5
- The
Washington Radiation for In-Stent Restenosis Trial
for Saphenous Vein Grafts (SVG WRIST)—Ron Waksman,
MD, Washington Hosp. Ctr., Washington, D.C., 3/18,
9:46 a.m., #22-11
- The
Beta-Cath System Trial—Richard E. Kuntz, MD,
Brigham & Women's Hosp., Boston, 3/18, 8:58 a.m.,
#22-3
Moderators:
Douglas Zipes, MD, ACC president-elect, Indiana Univ.
Sch. of Med., Indianapolis, and David Holmes, Jr., MD,
Mayo Clinic, Rochester, Minn.
Listen
to the news conference.
5:00-6:00
p.m.
Annual reception for ACC 2001 media attendees, Show
Office A4 Convention Center, third floor (across from
Media Complex)
MONDAY,
MARCH 19
Results from Monday
8:15-9:00
a.m.
New findings
will help doctors optimize care in heart attack treatment
- Clopidogrel
in Unstable Angina to Prevent Recurrent Ischemic Events
(CURE)—Salim Yusuf, MD, McMaster Univ., Hamilton,
Ontario, Canada, 3/19, 10:15 a.m., #405-9
- The
New Definition of Myocardial Infarction: What Does
It Mean Clinically?—Mark A. Meier, MD, Univ.
of Mich. at Ann Arbor, 3/18, 1-2 p.m., #1018-89
- Are
There High-Risk Patients Who Are Troponin Negative?
Further Risk Stratification With the TIMI Risk Score
in Patients With Acute Coronary Syndromes: Results
From OPUS-TIMI 16—Christopher P. Cannon, MD,
Brigham & Women's Hosp., Boston, 3/19, 11:30 a.m.,
#820-1
- Optimizing
Care in Acute MI: Report from the Guidelines Applied
in Practice Project—Kim A. Eagle, MD, Univ. of
Mich. at Ann Arbor, 3/19, 11 a.m.-noon, #703-3
Moderator:
Robert Califf, MD, Duke Clinical Research Institute, Duke
Univ., Durham, N.C.
Listen
to the news conference.
9:15–10:30
a.m.
Open to attend Late-Breaking Clinical Trials I, #405
10:45–11:30
a.m.
Studies probe
new approaches to angiogenesis
- Therapeutic
Angiogenesis With Recombinant Fibroblast Growth Factor-2
for Intermittent Claudication (TRAFFIC)—Robert
J. Lederman, MD, Nat. Heart Lung Inst., Bethesda,
Md., 3/19, 9:45 a.m., #405-5
- Adenovirus
FGF Angiogenic Gene Therapy (AGENT) Trial for Stable
Angina—Cindy Grines, MD, William Beaumont Hosp.,
Royal Oak, Mich., 3/19, 9:30 a.m., #405-3
- Patients
With Inadequate Coronary Collateral Support Are Resistant
to Angiogenic Growth Factors—Pier D. Lambiase,
MD, St. Thomas' Hosp., KCL, London, United Kingdom,
3/21, 8:45 a.m., #878-2
- A
Novel Ultrasound Method for Evaluation of Angiogenesis—Emile
Mohler, III, MD, Univ. of Pa., Philadelphia, 3/18,
3-4 p.m., #1074-159
Moderator:
Valentin Fuster, MD, PhD, Mt. Sinai Med. Ctr, New York
City
Listen
to the news conference.
12:30–1:15
p.m.
Studies shed
light on cardiovascular effects, safety of sildenafil
(Viagra®)
- Effect
of Sildenafil (Viagra®) on Wave Reflection: A New
Insight Into Its Cardiovascular Effects—Charalambos
Vlachopoulos, MD, Univ. of New S. Wales, Sydney, Australia,
3/19, 3-4 p.m., #1163-185
- Beneficial
Effects of a Phosphodiesterase Type 5 Inhibitor (Sildenafil)
on Exercise Neurohormonal Activation and Erectile
Dysfunction in Patients With Congestive Heart Failure-Infinity
Double-Blind Placebo-Controlled, Cross-Over Randomized
Study—Edimar A. Bocchi, MD, Heart Inst., Univ.
of Sao Paolo, Brazil, 3/19, 10:15 a.m., #812-5
- Sildenafil
Prescription-Event Monitoring Study. No Evidence of
an Increase in Cardiovascular Outcomes Among 5,000
Men Prescribed Sildenafil in General Practice in England—Saad
A.W. Shakir, MD, Drug Safety Research Unit, Southampton,
United Kingdom, 3/21, 9-10 a.m., #1302-162
Moderator:
Adolph Hutter, MD, Mass. Gen. Hosp., Boston
Listen
to the news conference.
TUESDAY,
MARCH 20
Results from Tuesday
7:30–8:15
a.m.
Clinical trials
broaden treatment options for heart failure patients
-
Multicenter InSync Randomized Clinical Evaluation
(MIRACLE): Results of a Randomized, Double-Blind,
Controlled Trial to Assess Cardiac Resynchronization
Therapy in Heart Failure Patients—William T.
Abraham, MD, Univ. of Ky., Lexington, 3/20, 8:45 a.m.,
#414-3
-
Carvedilol Post-Infarct Survival Control in Left Ventricular
Dysfunction (CAPRICORN)—Henry J. Dargie, MD,
Univ. of Glasgow, United Kingdom, 3/20, 9:15 a.m.,
#414-7
-
Carvedilol Prospective Randomized Cumulative Survival
Trial (COPERNICUS)—Milton Packer, MD, Columbia
Univ., New York City, 3/20, 9 a.m., #414-5
-
Prospective, Randomized, Double-Blind, Placebo-Controlled,
Multicenter Study of the Efficacy and Safety of Tezosentan
in Patients With Acute Decompensated Heart Failure
(RITZ-2)—Guillermo Torre-Amione, MD, Baylor College
of Med., Houston, 3/20, 9:30 a.m., #414-9
- Impact
and Limitations of Heart Failure Clinical Trials—
Barry Massie, MD, Univ. of Calif., San Francisco,
VA Med. Ctr., 3/20, 4-5 p.m., #645
Moderator:
Barry Massie, MD, Univ. of Calif., San Francisco, VA Med.
Ctr.
Listen
to the news conference.
8:30–10:00
a.m.
Open to attend Late-Breaking Clinical Trials II,
#414
10:15–11:00
a.m.
Studies highlight
progress in lipid-lowering therapy
- New
Statin Shows Promise—Evan A. Stein, MD
- ZD4522
(rosuvastatin) Compared With Diet and Maximal
Lipid Therapy in Patients With Heterozygous Familial
Hypercholesterolemia—Evan A. Stein, MD, Metabolic
& Atherosclerosis Res. Ctr., Highland Heights,
Ky., 3/20, 3-4 p.m., #1261-175
- ZD4522
Is Superior to Pravastatin and Simvastatin in
Reducing Low-Density Lipoprotein Cholesterol,
Enabling More Hypercholesterolemic Patients to
Achieve Low-Density Lipoprotein Cholesterol Guidelines—Rodolfo
Paoletti, MD, Inst. of Pharmacological Sc., 3/20,
3-4 p.m., #1261-174
- ZD4522
Is Superior to Atorvastatin in Decreasing Low
Density Lipoprotein Cholesterol and Increasing
High Density Lipoprotein Cholesterol in Patients
With Type IIa or IIb Hypercholesterolemia—Michael
H. Davidson, MD, Chicago Ctr. for Clin. Res.,
3/20, 3-4 p.m., #1261-175
- ZD4522
Is Superior to Atorvastatin in the Treatment of
Patients With Heterozygous Familial Hypercholesterolemia—Evan
Stein, MD, Metabolic & Atherosclerosis Res. Ctr.,
Highland Heights, Ky., 3/20, 3-4 p.m., #1261-176
- Hypercholesterolemia
Is Undertreated in Patients With Coronary Disease.
Results of a Survey in 1997 and a Survey in 2000—Frank
Vermeer, Univ. Hosp., Maastricht, the Netherlands,
3/19, 9-10 a.m., #1095-181
- Cholesterol
Self-Management: A New Way for Better Cholesterol
Control—Johannes
Schaar, MD, Univ. of Essen, Germany, 3/19, 3-4 p.m.,
#1161-175
- Stunning
Reduction in Death and Myocardial Infarction Observed
With Early Lipid-Lowering Therapy After Acute Coronary
Syndromes—Herbert
D. Aronow, MD, Clev. Clin. Foundation, Ohio, 3/19,
2 p.m., #831-1
- Lipid-Lowering
Drug Therapy During Hospitalization for Acute MI Is
Associated With Lower Postdischarge 1-Year Mortality—Robert
P. Giugliano, MD, Brigham & Women's Hosp., Boston,
3/18, 4-5 p.m., #1053-91
Moderator:
Richard Pasternak, MD, Mass. Gen. Hosp. Boston
Listen
to the news conference.
11:15
a.m.–Noon
Experts focus
cardiovascular spotlight on women and minorities
- Findings
and Recommendations of the Joint Committee on Ethnic
and Gender Disparities in Access to Quality Cardiovascular
Care—George Mensah, MD, Med. College of Ga.,
Atlanta, and Marian Limacher, MD, Univ. of Fla., Gainesville,
3/20, 4-5 p.m., #650
- Risk
Factors in Minority Populations: Report on Hypertension
in African Americans—Elizabeth Ofili, MD, Morehouse
Sch. of Med., Atlanta; Genetics and Heart Disease
in Hispanics—Jerry Nadler, MD, Univ. of Va.,
Charlottesville, 3/21, 8:30-10 a.m., #657
Moderator:
Charles Francis, MD, Charles R. Drew Univ. of Medicine
& Science, Los Angeles
Listen
to the news conference.
1:00–1:45
p.m.
Sessions highlight
importance—and controversies—of heart-healthy
diets
- Why
My Diet Is the Best—Robert Atkins, MD, Atkins
Ctr. for Comprehensive Med., New York City, and Dean
Ornish, MD, Preventive Med. Res. Inst., Sausalito,
Calif., 3/20, 10:30-noon, #635
- Results
of a Randomized Trial Comparing a High Fat Low Carbohydrate
Diet to the NCEP Step 2 Diet: Effect on LDL Cholesterol
Subclasses—Yamil Wady Aude, MD, Mt. Sinai Med.
Ctr., Warwick, R.I., 3/20, noon-1 p.m., #1226-164
- Extent
of Coronary Artery Calcification in Elderly Healthy
and Adventist Volunteers Compared to a Healthy Aged-Matched
General Population—Ross G.T. Walker, MD, Sydney
Heart Image of Sydney Adventist Hosp., Sydney, Australia,
3/18, 3-4 p.m., #1059-61
Moderator:
Paul Thompson, MD, Preventive Cardiology and Cholesterol
Management Ctr., Hartford Hosp., Hartford, Conn.
Listen
to the news conference.
WEDNESDAY,
MARCH 21
Results from Wednesday
8:30–10:00
a.m.
Open to attend Late-Breaking Clinical Trials III,
#423
7:15–8:00
a.m.
Clinical
trials examine cardiovascular benefits when treating
osteoporosis, reducing inflammatory markers, and administering
alternative therapy; cost benefits of aggressive treatment
also examined
-
Multiple Outcomes of Raloxifene Evaluation (MORE)—Elizabeth
Barrett-Connor, MD, Univ. of Calif., San Diego, 3/21,
8:30 a.m., #423-1
- The
Pravastatin Inflammation/CRP Evaluation (PRINCE)—Paul
M. Ridker, MD, Brigham & Women's Hosp., Boston, 3/21,
9 a.m., #423-5
-
Program to Assess Alternative Treatment Strategies
to Achieve Cardiac Health (PATCH): EDTA Study—D.
George Wyse, MD, Univ. of Calgary, Ontario, Canada,
3/21, 9:30 a.m., #423-9
- Treat
Angina With Aggrastat and Determine Cost of Therapy
With an Invasive or Conservative Strategy (TACTICS-TIMI-18)—William
S. Weintraub, MD, Emory Univ., Atlanta, 3/21, 9:15
a.m., #423-7
Moderator:
Robert Vogel, MD, University of Md., Baltimore
Listen
to the news conference.
|
